The Exubera story continues to fascinate Insider.
The latest twist in the tale is that Pfizer will now pay $1.3 billion (euro1.1 billion) to Sanofi-Aventis Group to obtain full rights to the inhaled insulin the companies developed jointly, along with Necktar.
The FDA are expected to rule upon the drug later this month.
Last September, an FDA expert panel voted to recommend inhaled insulin for approval but in October the agency said it wanted to extend its review of the medication by three months.
The buyout was, indeed, predicted by Insider back in October 2005!
Stick with PharmaGossip if you want the news.......even before it happens!